vs
Root, Inc.（ROOT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Root, Inc.的1.9倍（$772.1M vs $397.0M），Root, Inc.同比增速更快（21.5% vs 5.9%），过去两年Root, Inc.的营收复合增速更高（24.8% vs 9.0%）
Root Inc.旗下的Root保险公司是一家专注于汽车保险的线上保险公司，业务主要运营于美国地区，依托数字化技术为美国车主提供便捷的线上汽车保险服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ROOT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$397.0M
营收增速更快
ROOT
高出15.7%
5.9%
两年增速更快
ROOT
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $397.0M | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 2.6% | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | 21.5% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.35 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ROOTRVTY
| Q4 25 | $397.0M | $772.1M | ||
| Q3 25 | $387.8M | $698.9M | ||
| Q2 25 | $382.9M | $720.3M | ||
| Q1 25 | $349.4M | $664.8M | ||
| Q4 24 | $326.7M | $729.4M | ||
| Q3 24 | $305.7M | $684.0M | ||
| Q2 24 | $289.2M | $691.7M | ||
| Q1 24 | $254.9M | $649.9M |
净利润ROOTRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $-5.4M | $46.7M | ||
| Q2 25 | $22.0M | $53.9M | ||
| Q1 25 | $18.4M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $22.8M | $94.4M | ||
| Q2 24 | $-7.8M | $55.4M | ||
| Q1 24 | $-6.2M | $26.0M |
毛利率ROOTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率ROOTRVTY
| Q4 25 | 2.6% | 14.5% | ||
| Q3 25 | 0.1% | 11.7% | ||
| Q2 25 | 7.1% | 12.6% | ||
| Q1 25 | 6.8% | 10.9% | ||
| Q4 24 | 10.7% | 16.3% | ||
| Q3 24 | 11.3% | 14.3% | ||
| Q2 24 | 1.3% | 12.4% | ||
| Q1 24 | 2.1% | 6.8% |
净利率ROOTRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | -1.4% | 6.7% | ||
| Q2 25 | 5.7% | 7.5% | ||
| Q1 25 | 5.3% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 7.5% | 13.8% | ||
| Q2 24 | -2.7% | 8.0% | ||
| Q1 24 | -2.4% | 4.0% |
每股收益（稀释后）ROOTRVTY
| Q4 25 | $0.35 | $0.86 | ||
| Q3 25 | $-0.35 | $0.40 | ||
| Q2 25 | $1.29 | $0.46 | ||
| Q1 25 | $1.07 | $0.35 | ||
| Q4 24 | $1.42 | $0.77 | ||
| Q3 24 | $1.35 | $0.77 | ||
| Q2 24 | $-0.52 | $0.45 | ||
| Q1 24 | $-0.42 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $669.3M | $919.9M |
| 总债务越低越好 | $200.3M | — |
| 股东权益账面价值 | $284.3M | $7.3B |
| 总资产 | $1.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.70× | — |
8季度趋势，按日历期对齐
现金及短期投资ROOTRVTY
| Q4 25 | $669.3M | $919.9M | ||
| Q3 25 | $653.3M | $931.4M | ||
| Q2 25 | $641.4M | $991.8M | ||
| Q1 25 | $609.4M | $1.1B | ||
| Q4 24 | $599.3M | $1.2B | ||
| Q3 24 | $674.8M | $1.2B | ||
| Q2 24 | $667.2M | $2.0B | ||
| Q1 24 | $640.5M | $1.7B |
总债务ROOTRVTY
| Q4 25 | $200.3M | — | ||
| Q3 25 | $200.4M | — | ||
| Q2 25 | $200.1M | — | ||
| Q1 25 | $200.0M | — | ||
| Q4 24 | $200.1M | — | ||
| Q3 24 | $300.9M | — | ||
| Q2 24 | $300.1M | — | ||
| Q1 24 | $299.3M | — |
股东权益ROOTRVTY
| Q4 25 | $284.3M | $7.3B | ||
| Q3 25 | $265.0M | $7.4B | ||
| Q2 25 | $244.5M | $7.6B | ||
| Q1 25 | $228.7M | $7.6B | ||
| Q4 24 | $203.7M | $7.7B | ||
| Q3 24 | $181.9M | $7.9B | ||
| Q2 24 | $151.3M | $7.9B | ||
| Q1 24 | $165.7M | $7.8B |
总资产ROOTRVTY
| Q4 25 | $1.7B | $12.2B | ||
| Q3 25 | $1.6B | $12.1B | ||
| Q2 25 | $1.6B | $12.4B | ||
| Q1 25 | $1.6B | $12.4B | ||
| Q4 24 | $1.5B | $12.4B | ||
| Q3 24 | $1.6B | $12.8B | ||
| Q2 24 | $1.5B | $13.4B | ||
| Q1 24 | $1.4B | $13.4B |
负债/权益比ROOTRVTY
| Q4 25 | 0.70× | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 0.98× | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 1.81× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $206.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | 0.0% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ROOTRVTY
| Q4 25 | $206.5M | $182.0M | ||
| Q3 25 | $57.6M | $138.5M | ||
| Q2 25 | $52.0M | $134.3M | ||
| Q1 25 | $26.8M | $128.2M | ||
| Q4 24 | $195.7M | $174.2M | ||
| Q3 24 | $49.4M | $147.9M | ||
| Q2 24 | $62.6M | $158.6M | ||
| Q1 24 | $14.5M | $147.6M |
自由现金流ROOTRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | $195.3M | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | $62.4M | $136.6M | ||
| Q1 24 | $14.3M | $129.7M |
自由现金流率ROOTRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | 59.8% | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | 21.6% | 19.7% | ||
| Q1 24 | 5.6% | 20.0% |
资本支出强度ROOTRVTY
| Q4 25 | 0.0% | 2.6% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.1% | 3.4% | ||
| Q3 24 | 0.0% | 3.3% | ||
| Q2 24 | 0.1% | 3.2% | ||
| Q1 24 | 0.1% | 2.7% |
现金转化率ROOTRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 2.36× | 2.49× | ||
| Q1 25 | 1.46× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.17× | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ROOT
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
